OBJECTIVE: Clozapine is the most powerful new‐generation antipsychotic. Although this drug leads to great therapeutic benefits, two types of undesirable conditions frequently occur with its use: side effects and resistance to treatment. Therapeutic drug monitoring of clozapine would be very useful to avoid both these situations. The necessity of monitoring the therapy is the result of a wide interindividual variability in the metabolism of clozapine. In this review, we highlight all the conditions underlying this variability, analyzing them one by one. METHODS: Relevant literature was identified through a search of MEDLINE and PubMed. In addition, the case of a treatment‐resistant patient with accelerated metabolism of clozapine is reported as representative of utility of therapeutic drug monitoring in terms of clozapine dose adjustment. RESULTS: Genetic polymorphisms of cytochrome P450 enzymes and of neurotransmitter receptors; drug interactions; interactions of clozapine with other substances such as food and drink; smoking; and nonmodifiable variables such as age, ethnicity, and gender have been examined in relation to the existing scientific literature. The laboratory techniques that clinicians could use to identify these variables and adequate therapies are also reviewed.
OBJECTIVE:Clozapine is the most powerful new‐generation antipsychotic. Although this drug leads to great therapeutic benefits, two types of undesirable conditions frequently occur with its use: side effects and resistance to treatment. Therapeutic drug monitoring of clozapine would be very useful to avoid both these situations. The necessity of monitoring the therapy is the result of a wide interindividual variability in the metabolism of clozapine. In this review, we highlight all the conditions underlying this variability, analyzing them one by one. METHODS: Relevant literature was identified through a search of MEDLINE and PubMed. In addition, the case of a treatment‐resistant patient with accelerated metabolism of clozapine is reported as representative of utility of therapeutic drug monitoring in terms of clozapine dose adjustment. RESULTS: Genetic polymorphisms of cytochrome P450 enzymes and of neurotransmitter receptors; drug interactions; interactions of clozapine with other substances such as food and drink; smoking; and nonmodifiable variables such as age, ethnicity, and gender have been examined in relation to the existing scientific literature. The laboratory techniques that clinicians could use to identify these variables and adequate therapies are also reviewed.
Authors: Eric Olsson; Gunnar Edman; Leif Bertilsson; Dzana Sudic Hukic; Catharina Lavebratt; Sven V Eriksson; Urban Ösby Journal: Prim Care Companion CNS Disord Date: 2015-02-19
Authors: Amedeo Minichino; Francesco Saverio Bersani; Wanda Katharina Calò; Francesco Spagnoli; Marta Francesconi; Roberto Vicinanza; Roberto Delle Chiaie; Massimo Biondi Journal: Int J Environ Res Public Health Date: 2013-10-10 Impact factor: 3.390
Authors: F Saverio Bersani; Marialuce Coviello; Claudio Imperatori; Marta Francesconi; Christina M Hough; Giuseppe Valeriani; Gianfranco De Stefano; Flaminia Bolzan Mariotti Posocco; Rita Santacroce; Amedeo Minichino; Ornella Corazza Journal: Biomed Res Int Date: 2015-09-17 Impact factor: 3.411
Authors: Kenneth H Wills; Stephen J Behan; Michael J Nance; Jessica L Dawson; Thomas M Polasek; Ashley M Hopkins; Madelé van Dyk; Andrew Rowland Journal: Pharmaceutics Date: 2021-12-27 Impact factor: 6.321